Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

Official Title: Phase II Study of Peginterferon Alfa-2b (PEGIntron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma

This phase II trial studies how well peginterferon alfa-2b works in treating younger patients with craniopharyngioma that is recurrent or cannot be removed by surgery. Peginterferon alfa-2b may interfere with the growth of tumor cells and slow the growth of craniopharyngioma.

Goldman, Stewart, MD

Contact Information:

Stewart Goldman, MD